Last reviewed · How we verify
tumor neoantigen specific T cell — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
tumor neoantigen specific T cell (tumor neoantigen specific T cell) — JIANG LONGWEI.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| tumor neoantigen specific T cell TARGET | tumor neoantigen specific T cell | JIANG LONGWEI | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- tumor neoantigen specific T cell CI watch — RSS
- tumor neoantigen specific T cell CI watch — Atom
- tumor neoantigen specific T cell CI watch — JSON
- tumor neoantigen specific T cell alone — RSS
Cite this brief
Drug Landscape (2026). tumor neoantigen specific T cell — Competitive Intelligence Brief. https://druglandscape.com/ci/tumor-neoantigen-specific-t-cell. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab